ScoreWhy is PharmaBlock Sciences (Nanjing), Inc. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 12.32% and Operating profit at -4.94% over the last 5 years
2
Positive results in Mar 26
- DEBT-EQUITY RATIO (HY) Lowest at -16.12 %
- RAW MATERIAL COST(Y) Fallen by -12.91% (YoY)
- INVENTORY TURNOVER RATIO(HY) Highest at 1.97 times
3
With ROE of 3.52%, it has a fair valuation with a 1.09 Price to Book Value
- Over the past year, while the stock has generated a return of -0.06%, its profits have fallen by -6%
- At the current price, the company has a high dividend yield of 0
4
Below par performance in long term as well as near term
- Along with generating -0.06% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to PharmaBlock Sciences (Nanjing), Inc. should be less than 10%
- Overall Portfolio exposure to Miscellaneous should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Miscellaneous)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is PharmaBlock Sciences (Nanjing), Inc. for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
PharmaBlock Sciences (Nanjing), Inc.
-0.06%
0.42
42.07%
China Shanghai Composite
21.43%
1.55
13.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
12.32%
EBIT Growth (5y)
-4.94%
EBIT to Interest (avg)
36.57
Debt to EBITDA (avg)
1.36
Net Debt to Equity (avg)
0.16
Sales to Capital Employed (avg)
0.36
Tax Ratio
10.97%
Dividend Payout Ratio
31.82%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.85%
ROE (avg)
11.32%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
31
Industry P/E
Price to Book Value
1.09
EV to EBIT
26.75
EV to EBITDA
16.99
EV to Capital Employed
1.11
EV to Sales
2.51
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
4.14%
ROE (Latest)
3.52%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
DEBT-EQUITY RATIO
(HY)
Lowest at -16.12 %
RAW MATERIAL COST(Y)
Fallen by -12.91% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 1.97 times
-2What is not working for the Company
OPERATING PROFIT(Q)
Lowest at CNY 49.29 MM
OPERATING PROFIT MARGIN(Q)
Lowest at 9.7 %
Here's what is working for PharmaBlock Sciences (Nanjing), Inc.
Debt-Equity Ratio
Lowest at -16.12 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Inventory Turnover Ratio
Highest at 1.97 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by -12.91% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for PharmaBlock Sciences (Nanjing), Inc.
Operating Profit
Lowest at CNY 49.29 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (CNY MM)
Operating Profit Margin
Lowest at 9.7 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
